Granite Islands Private Wealth LLC Increases Position in Eli Lilly and Company $LLY

Key Points

• Granite Islands Private Wealth increased its Eli Lilly stake by 132% in the first quarter, buying 957 additional shares and bringing its total to 1,682 shares worth about $1.54 million.
• Investor attention remains centered on Lilly’s obesity and diabetes franchise, including a Medicare GLP-1 Bridge program that could expand access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1.
• Lilly is also getting a boost from its pipeline and regulatory progress, including a CHMP recommendation for Jaypirca (pirtobrutinib) in the EU and continued analyst optimism, with the stock carrying a Moderate Buy consensus and a $1,235.07 price target.

Granite Islands Private Wealth LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 132.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,682 shares of the company's stock after purchasing an additional 957 shares during the period. Eli Lilly and Company comprises approximately 1.4% of Granite Islands Private Wealth LLC's portfolio, making the stock its 20th largest position. Granite Islands Private Wealth LLC's holdings in Eli Lilly and Company were worth $1,539,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $12,976,634,000. Capital Research Global Investors boosted its holdings in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. J. Stern & Co. LLP boosted its holdings in Eli Lilly and Company by 46,191.3% in the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock valued at $4,047,245,000 after purchasing an additional 4,038,502 shares in the last quarter. Cardano Risk Management B.V. increased its stake in Eli Lilly and Company by 876.1% in the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock valued at $2,552,419,000 after purchasing an additional 2,131,734 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Rothschild & Co Redburn boosted their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Monday, June 22nd. Royal Bank Of Canada reissued an "outperform" rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Sanford C. Bernstein restated an "outperform" rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Finally, Bank of America raised their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a "buy" rating in a report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,235.07.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,206.51 on Monday. The firm's fifty day simple moving average is $1,036.28 and its 200-day simple moving average is $1,021.13. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,215.76. The stock has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 42.86, a PEG ratio of 1.32 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company's revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.